Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoki Hashimoto

Showing results (231-240 of 249) with videos related to

Pageof 25
Sort By:
Neuropsychopharmacology Reports|November 17, 2022
Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood DisordersKentaro Fukumoto, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Psychiatry and Clinical Neurosciences|October 10, 2022
Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications: a propensity score-matched analysisTakashi Tsuboi, Yoshikazu Takaesu, Naomi Hasegawa, et al.
Molecular Psychiatry|November 30, 2019
White matter microstructural alterations across four major psychiatric disorders: mega-analysis study in 2937 individualsDaisuke Koshiyama, Masaki Fukunaga, Naohiro Okada, et al.
Annals of General Psychiatry|December 25, 2022
The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the "Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)" projectYoshitaka Kyou, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Psychiatry and Clinical Neurosciences|March 11, 2026
Psychometrics of BE-PSD-V2.0 and its correspondence with PANSS and CGI-SHiroyoshi Takeuchi, Naoki Hashimoto, Yoshiteru Takekita, et al.
Frontiers in Psychiatry|June 3, 2022
Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital CharacteristicsHikaru Hori, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|October 18, 2022
Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia"Ken Inada, Kentaro Fukumoto, Naomi Hasegawa, et al.
Journal of Clinical Psychopharmacology|October 4, 2022
Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With SchizophreniaTsuyoshi Okada, Hikaru Hori, Naomi Hasegawa, et al.
Psychiatry and Clinical Neurosciences|September 9, 2023
Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter studyNaomi Hasegawa, Yuka Yasuda, Norio Yasui-Furukori, et al.
Neuropsychopharmacology Reports|February 26, 2025
Proposal for a Novel Classification of Patients With Enlarged Ventricles and Cognitive Impairment Based on Data-Driven Analysis of Neuroimaging Results in Patients With Psychiatric DisordersYuka Yasuda, Satsuki Ito, Junya Matsumoto, et al.
Pageof 25

Showing results (231-240 of 249) with videos related to

Sort By:
Pageof 25
Neuropsychopharmacology Reports|November 17, 2022
Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood DisordersKentaro Fukumoto, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Psychiatry and Clinical Neurosciences|October 10, 2022
Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications: a propensity score-matched analysisTakashi Tsuboi, Yoshikazu Takaesu, Naomi Hasegawa, et al.
Molecular Psychiatry|November 30, 2019
White matter microstructural alterations across four major psychiatric disorders: mega-analysis study in 2937 individualsDaisuke Koshiyama, Masaki Fukunaga, Naohiro Okada, et al.
Annals of General Psychiatry|December 25, 2022
The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the "Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)" projectYoshitaka Kyou, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Psychiatry and Clinical Neurosciences|March 11, 2026
Psychometrics of BE-PSD-V2.0 and its correspondence with PANSS and CGI-SHiroyoshi Takeuchi, Naoki Hashimoto, Yoshiteru Takekita, et al.
Frontiers in Psychiatry|June 3, 2022
Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital CharacteristicsHikaru Hori, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|October 18, 2022
Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia"Ken Inada, Kentaro Fukumoto, Naomi Hasegawa, et al.
Journal of Clinical Psychopharmacology|October 4, 2022
Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With SchizophreniaTsuyoshi Okada, Hikaru Hori, Naomi Hasegawa, et al.
Psychiatry and Clinical Neurosciences|September 9, 2023
Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter studyNaomi Hasegawa, Yuka Yasuda, Norio Yasui-Furukori, et al.
Neuropsychopharmacology Reports|February 26, 2025
Proposal for a Novel Classification of Patients With Enlarged Ventricles and Cognitive Impairment Based on Data-Driven Analysis of Neuroimaging Results in Patients With Psychiatric DisordersYuka Yasuda, Satsuki Ito, Junya Matsumoto, et al.
Pageof 25